L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Current Portion of Long-Term Debt
kr451k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Current Portion of Long-Term Debt
kr95.5m
CAGR 3-Years
104%
CAGR 5-Years
28%
CAGR 10-Years
6%
B
Bergenbio ASA
OSE:BGBIO
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Current Portion of Long-Term Debt
kr3.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nykode Therapeutics ASA
OSE:NYKD
Current Portion of Long-Term Debt
$1.4m
CAGR 3-Years
144%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Current Portion of Long-Term Debt
kr400k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
451k NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Current Portion of Long-Term Debt amounts to 451k NOK.

What is Lytix Biopharma AS's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
-48%

Over the last year, the Current Portion of Long-Term Debt growth was -48%.

Back to Top